Companies
Felix Biotechnology
backed by the Cystic Fibrosis Foundation, is running the Yale-based CYPHY Phase 1/2 trial of YPT-01 against chronic P. aeruginosa lung infection in CF patients — a chronic, biofilm-forming indication where conventional antibiotics manage but rarely clear infection.
- Country
- United States
Clinical
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bacteriophage therapy | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.